Breast cancer vaccine BP1 7 - Biomira

Drug Profile

Breast cancer vaccine BP1 7 - Biomira

Alternative Names: BLP16; BP1 7-KLH; Cancer vaccine BP1 7 - Biomira

Latest Information Update: 28 Jul 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomira
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 28 Jul 1999 A study has been added to the Cancer immunogenicity section
  • 10 Mar 1997 Phase-I clinical trials for Breast cancer in USA (Unknown route)
  • 20 Feb 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top